-
Je něco špatně v tomto záznamu ?
Putative Nox2 inhibitors worsen homocysteine-induced impaired acetylcholine-mediated relaxation
RM. Smith, S. Rai, P. Kruzliak, A. Hayes, A. Zulli,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- acetofenony farmakologie MeSH
- acetylcholin farmakologie MeSH
- aorta účinky léků enzymologie MeSH
- fosforylace MeSH
- glykoproteiny farmakologie MeSH
- homocystein farmakologie MeSH
- inhibitory enzymů farmakologie MeSH
- králíci MeSH
- myši inbrední C57BL MeSH
- myši knockoutované MeSH
- NADPH-oxidasa 2 antagonisté a inhibitory genetika metabolismus MeSH
- serin MeSH
- synthasa oxidu dusnatého, typ III metabolismus MeSH
- techniky in vitro MeSH
- threonin MeSH
- vazodilatace účinky léků MeSH
- vazodilatancia farmakologie MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND AND AIM: Increased homocysteine (Hcy) is associated with coronary artery disease (CAD). Hcy increases reactive oxygen species (ROS) via NADPH oxidases (Nox), reducing acetylcholine-mediated vasorelaxation. We aimed to determine if putative Nox2 inhibitors prevent Hcy-impaired acetylcholine-mediated vasorelaxation. METHODS AND RESULTS: New Zealand White rabbit and wild-type (C57BL/6) and Nox2-/- (NOX) mice aortic rings were mounted in organ baths. Rabbit rings were incubated with either apocynin (10 μM), gp91ds-tat (GP, 1 μM) or PhoxI2 (1 μM) and mice rings GP (1 μM) only. Some rabbit rings were incubated with 3 mM Hcy, before pre-contraction, followed by dose-response relaxation to acetylcholine (ACh; 0.01μM-10μM). In rabbit rings treated with Hcy and GP, O2‾ donor pyrogallol (1 μM) or Akt activator SC79 (1 μM) was added 5 min before ACh. Mice rings were used to compare Nox2 deletion to normal acetylcholine-mediated relaxation. In rabbits, Hcy reduced acetylcholine-mediated relaxation vs. control (p < 0.0001). Treatment + Hcy reduced relaxation compared with treatment alone (p < 0.0001). Pyrogallol and SC79 reversed the response of GP + Hcy (p = 0.0001). In mice, Nox2 deletion reduced acetylcholine-mediated vasorelaxation. Rabbit tissue analysis revealed that Hcy reduced eNOS phosphorylation at Thr495 and increased eNOS phosphorylation at Ser1177; no further alteration at Thr495 was observed with GP. In contrast, GP prevented increased phosphorylation at Ser1177. CONCLUSIONS: Apocynin, GP and PhoxI2 worsens acetylcholine-mediated vascular relaxation in rabbit aorta, which is supported by results from mouse Nox2 deletion data. These inhibitors worsen Hcy-induced vascular dysfunction, suggesting that current putative Nox2 inhibitors might not be useful in treating HHcy.
Department of Internal Medicine Brothers of Mercy Hospital Brno Czechia
Institute for Health and Sport Victoria University Footscray Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006189
- 003
- CZ-PrNML
- 005
- 20200526093910.0
- 007
- ta
- 008
- 200511s2019 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.numecd.2019.05.051 $2 doi
- 035 __
- $a (PubMed)31272869
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Smith, Renee M $u Institute for Health and Sport, Victoria University, Footscray, Australia. Electronic address: Renee.Smith1@live.vu.edu.au.
- 245 10
- $a Putative Nox2 inhibitors worsen homocysteine-induced impaired acetylcholine-mediated relaxation / $c RM. Smith, S. Rai, P. Kruzliak, A. Hayes, A. Zulli,
- 520 9_
- $a BACKGROUND AND AIM: Increased homocysteine (Hcy) is associated with coronary artery disease (CAD). Hcy increases reactive oxygen species (ROS) via NADPH oxidases (Nox), reducing acetylcholine-mediated vasorelaxation. We aimed to determine if putative Nox2 inhibitors prevent Hcy-impaired acetylcholine-mediated vasorelaxation. METHODS AND RESULTS: New Zealand White rabbit and wild-type (C57BL/6) and Nox2-/- (NOX) mice aortic rings were mounted in organ baths. Rabbit rings were incubated with either apocynin (10 μM), gp91ds-tat (GP, 1 μM) or PhoxI2 (1 μM) and mice rings GP (1 μM) only. Some rabbit rings were incubated with 3 mM Hcy, before pre-contraction, followed by dose-response relaxation to acetylcholine (ACh; 0.01μM-10μM). In rabbit rings treated with Hcy and GP, O2‾ donor pyrogallol (1 μM) or Akt activator SC79 (1 μM) was added 5 min before ACh. Mice rings were used to compare Nox2 deletion to normal acetylcholine-mediated relaxation. In rabbits, Hcy reduced acetylcholine-mediated relaxation vs. control (p < 0.0001). Treatment + Hcy reduced relaxation compared with treatment alone (p < 0.0001). Pyrogallol and SC79 reversed the response of GP + Hcy (p = 0.0001). In mice, Nox2 deletion reduced acetylcholine-mediated vasorelaxation. Rabbit tissue analysis revealed that Hcy reduced eNOS phosphorylation at Thr495 and increased eNOS phosphorylation at Ser1177; no further alteration at Thr495 was observed with GP. In contrast, GP prevented increased phosphorylation at Ser1177. CONCLUSIONS: Apocynin, GP and PhoxI2 worsens acetylcholine-mediated vascular relaxation in rabbit aorta, which is supported by results from mouse Nox2 deletion data. These inhibitors worsen Hcy-induced vascular dysfunction, suggesting that current putative Nox2 inhibitors might not be useful in treating HHcy.
- 650 _2
- $a acetofenony $x farmakologie $7 D000098
- 650 _2
- $a acetylcholin $x farmakologie $7 D000109
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a aorta $x účinky léků $x enzymologie $7 D001011
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a glykoproteiny $x farmakologie $7 D006023
- 650 _2
- $a homocystein $x farmakologie $7 D006710
- 650 _2
- $a techniky in vitro $7 D066298
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a myši knockoutované $7 D018345
- 650 _2
- $a NADPH-oxidasa 2 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D000074662
- 650 _2
- $a synthasa oxidu dusnatého, typ III $x metabolismus $7 D052250
- 650 _2
- $a fosforylace $7 D010766
- 650 _2
- $a králíci $7 D011817
- 650 _2
- $a serin $7 D012694
- 650 _2
- $a threonin $7 D013912
- 650 _2
- $a vazodilatace $x účinky léků $7 D014664
- 650 _2
- $a vazodilatancia $x farmakologie $7 D014665
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rai, Sudarshan $u Institute for Health and Sport, Victoria University, Footscray, Australia. Electronic address: Sudarshan.rai@vu.edu.au.
- 700 1_
- $a Kruzliak, Peter $u Department of Internal Medicine, Brothers of Mercy Hospital, Brno, Czechia; 2nd Department of Surgery, Center for Vascular Disease, Faculty of Medicine, Masaryk University, St. Anne's University Hospital, Brno, Czechia. Electronic address: peter.kruzliak@savba.sk.
- 700 1_
- $a Hayes, Alan $u Institute for Health and Sport, Victoria University, Footscray, Australia. Electronic address: alan.hayes@vu.edu.au.
- 700 1_
- $a Zulli, Anthony $u Institute for Health and Sport, Victoria University, Footscray, Australia. Electronic address: Anthony.zulli@vu.edu.au.
- 773 0_
- $w MED00003575 $t Nutrition, metabolism, and cardiovascular diseases : NMCD $x 1590-3729 $g Roč. 29, č. 8 (2019), s. 856-864
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31272869 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200526093906 $b ABA008
- 999 __
- $a ok $b bmc $g 1525047 $s 1096245
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 29 $c 8 $d 856-864 $e 20190511 $i 1590-3729 $m NMCD. Nutrition Metabolism and Cardiovascular Diseases $n Nutr Metab Cardiovasc Dis $x MED00003575
- LZP __
- $a Pubmed-20200511
